Last reviewed · How we verify

Dosing of enoxaparin for VTE prophylaxis — Competitive Intelligence Brief

Dosing of enoxaparin for VTE prophylaxis (Dosing of enoxaparin for VTE prophylaxis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dosing of enoxaparin for VTE prophylaxis (Dosing of enoxaparin for VTE prophylaxis) — Intermountain Health Care, Inc.. Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dosing of enoxaparin for VTE prophylaxis TARGET Dosing of enoxaparin for VTE prophylaxis Intermountain Health Care, Inc. marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement)
innohep® innohep® LEO Pharma marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)
Intermediate dose enoxaparin Intermediate dose enoxaparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Coagulation factors Xa and IIa (via antithrombin III)
enoxaparin/tinzaparin/dalteparin enoxaparin/tinzaparin/dalteparin Helsinki University Central Hospital marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Factor IIa
dose adaptation of Enoxaparin dose adaptation of Enoxaparin French Cardiology Society marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement)
Enoxaparin (High-dose Group) Enoxaparin (High-dose Group) Peking Union Medical College Hospital marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Coagulation factors Xa and IIa (indirect targets)
Enoxaparin Injectable Solution Enoxaparin Injectable Solution Medical University of Vienna marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Coagulation factors Xa and IIa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
  2. University of Melbourne · 3 drugs in this class
  3. French Cardiology Society · 2 drugs in this class
  4. Ottawa Hospital Research Institute · 2 drugs in this class
  5. McMaster University · 2 drugs in this class
  6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
  7. GlaxoSmithKline · 1 drug in this class
  8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
  10. Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dosing of enoxaparin for VTE prophylaxis — Competitive Intelligence Brief. https://druglandscape.com/ci/dosing-of-enoxaparin-for-vte-prophylaxis. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: